Skip to main content

Peer Review reports

From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

Original Submission
8 Jun 2022 Submitted Original manuscript
20 Jun 2022 Reviewed Reviewer Report
23 Jun 2022 Reviewed Reviewer Report
6 Jul 2022 Author responded Author comments - Shengyuan Yu
Resubmission - Version 2
6 Jul 2022 Submitted Manuscript version 2
Publishing
7 Jul 2022 Editorially accepted
28 Jul 2022 Article published 10.1186/s10194-022-01458-0

You can find further information about peer review here.

Back to article page